mTOR inhibitors in breast cancer: A systematic review

► This is the first systematic review regarding mTOR inhibitors in breast cancer. ► The BOLERO-2 study has marked a turning point regarding everolimus for ER-positive breast cancer. ► Everolimus may provide an avenue for achieving long-lasting benefit in HER2-positive patients.